Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Elafibranor (GFT505), an experimental drug for diabetes, insulin resistance, dyslipidemia, nonalcoholic steatohepatitis (NASH), increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 31/January/2018, 6.00 am